Hematology
News
Drugs
Xagena Medicine
Xagena.net
Efficacy and safety of Arzerra in patients with Fludarabine and Alemtuzumab-refractory chronic lymphocytic leukemia
Chronic lymphocytic leukaemia, refractory to Fludarabine and Alemtuzumab: Ofatumumab
JAK inhibitor produces significant relief for patients with myelofibrosis
2010 - Chronic lymphoid leukemia: CAL-101, an experimental agent, shows benefits
Azacitidine improves overall survival in intermediate-2 and high-risk myelodysplastic syndromes and acute myeloid leukaemia
Multiple myeloma: high response rate with Lenalidomide, Bortezomib and Dexamethasone
Newly diagnosed myeloma: better short-term overall survival and lower toxicity with Lenalidomide plus low-dose Dexamethasone
Radiolabeled antibody and stem cell transplantation to successfully treat advanced leukemia
Fludarabine- and Alemtuzumab-refractory chronic lymphocytic leukaemia: high response rates in patients treated with Arzerra
Idiopathic thrombocytopenic purpura: Revolade increases platelet levels and reduces bleeding
Promacta boosts platelets in patients with immune thrombocytopenic purpura
Advanced indolent lymphoma: maintenance therapy with MabThera is useful
Lenalidomide in elderly with chronic lymphocytic leukaemia is safe as single therapy
Cancer stem cells for multiple myeloma resist to treatments
Survival benefit in higher risk myelodysplastic syndrome patients treated with Azacitidine extends to those with acute myeloid leukemia
Fetal abnormalities caused by Glivec during pregnancy
Infection-related deaths after treatment with MabCampath in patients with B-cell chronic lymphocytic leukemia
Glivec is effective in systemic mastocytosis
Hepatic renal gastrointestinal adverse effects linked to Exjade for the treatment of chronic iron overload
Statins do not interfere with Rituximab to treat lymphoma
Better outcomes with new therapies for thrombocytopenia
Idiopathic thrombocytopenic purpura: MabThera and Dexamethasone compared to Dexamethasone alone
Second generation monoclonal antibody provides benefit for patients with follicular lymphoma
Long-term treatment with Revolade in chronic idiopathic thrombocytopenic purpura
Follicular non-Hodgkin lymphoma: Zevalin is safe and effective after chemotheraphy
Nexavar in the treatment of acute myeloid leukemia
Long-term remission of follicular lymphoma caused by gentler chemotherapy before stem cell transplant
Nexavar targets mutant FLT3 gene, a mutation associated with acute myeloid leukemia
New therapies for leukemia and lymphoma improve response rates and progression-free survival
Zevalin after chemotheraphy safe and effective for follicular non-Hodgkin lymphoma
Next Pages [
1
]
2
3
4
Web
Xagena News
Link
•
Allergology
•
Andrology
•
Biomedicine
•
Cardiology
•
Dermatology
•
Diabetology
•
Diagnostics
•
Drugs
•
Endocrinology
•
Gastroenterology
•
Gene Medicine
•
Gynecology
•
Hematology
•
Hepatology
•
Infectivology
•
Metabolism
•
Nephrology
•
Neurology
•
Oncology
•
Ophthalmology
•
Pediatrics
•
Pharmacology
•
Pneumology
•
Psychiatry
•
Rheumatology
•
Stem Therapy
•
Urology
•
Vaccines
•
Virology
n
Xagena.it
Powered by Luca Malattia -
LM Web Solutions
